PLYMOUTH MEETING, Pa., March 18, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today the appointment of Scott M. White, M.D. as Vice President, Clinical Development – Infectious Diseases. Dr. White will be responsible for advancing Inovio's infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
Inovio is advancing a robust clinical pipeline of therapies and vaccines for infectious diseases including hepatitis B and C, HIV, influenza, Ebola and other tropical diseases.
Dr. White joins Inovio from GlaxoSmithKline where he spent more than a decade in positions of increasing responsibility leading global infectious disease clinical development programs. His most recent position was Senior Director and Project Physician Leader for skin-related infections. He led multiple programs within the Infectious Diseases Therapy Area with international responsibilities from clinical trials to business and market development. In his GSK career, Dr. White built strong relationships with the FDA, EMEA and other regulatory and government agencies. Most notable was his leadership in the design and implementation of a pioneering European antibacterial clinical development network through a public private partnership between the European Commission and EFPIA (European Federation of Pharmaceutical Industries and Associations).
Dr. J. Joseph Kim, President & CEO of Inovio, said, "Scott will bring to Inovio his global experience and expert judgment in advancing infectious disease therapies and vaccines through numerous country regulatory agencies. As we ramp up clinical development of our rich pipeline, Inovio has now attracted three cancer and infectious disease opinion leaders this year. Their counsel as M.D.'s will be invaluable to Inovio as we move our vaccines and immunotherapies closer to market."
Dr. White, who earned his M.D. at the Pennsylvania State University College of Medicine, was an Edward J. Wing Fellow in Infectious Diseases at the University of Pittsburgh Medical Center. He also was assistant professor at Baylor College of Medicine and The University of Pittsburgh School of Medicine as well as lead author of numerous scientific publications.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.